Search
Cyclerion Therapeutics Inc
CYCNAdd to Watchlist
33.720USD
+2.490+7.97%
Close 09-08 16:00（ET）
14.32MMarket Cap
LossP/E TTM
More Details of Cyclerion Therapeutics Inc Company
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Cyclerion Therapeutics Inc Profile
Ticker SymbolCYCN
Company nameCyclerion Therapeutics Inc
IPO dateMar 18, 2019
CEOGraul (Regina M)
Number of employees1
Security typeOrdinary Share
Fiscal year-endMar 18
Address301 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16176217722
Websitehttps://www.cyclerion.com/
Ticker SymbolCYCN
IPO dateMar 18, 2019
CEOGraul (Regina M)
Company Executives of Cyclerion Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
64.03K
-24.76%
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
29.63K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.14K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
4.39K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
2.86K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark J. Vignola, Ph.D.
Dr. Mark J. Vignola, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Leoni, M.D.
Dr. Matthew Leoni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
64.03K
-24.76%
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
29.63K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.14K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
4.39K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
2.86K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Cyclerion Therapeutics Inc?
The top five shareholders of Cyclerion Therapeutics Inc are: Dr. Peter M. Hecht, Ph.D.
How many institutions hold shares of Cyclerion Therapeutics Inc (CYCN)?
As of 2026Q1, 37 institutions hold shares of Cyclerion Therapeutics Inc, with a combined market value of approximately 318.08K, accounting for 7.35% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -667233.00.